Is PLIANT THERAPEUTICS, INC. (PLRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 73.6% / 30% | 435.3% / 30% | 2.8% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 73.6% / 33% | 435.3% / 33% | 2.8% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 15.2% / 33% | 89.6% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 73.6% / 33% | 435.3% / 33% | 2.8% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 15.2% / 33% | 89.6% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -61.5% | |
| Return on Assets (ROA) | -30.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$128M |
| Free Cash Flow | -$129M |
| Total Debt | $29M |
| Debt-to-Equity | 16.1 |
| Current Ratio | 12.0 |
| Total Assets | $225M |
Price & Trading
| Last Close | $1.23 |
| 50-Day MA | $1.26 |
| 200-Day MA | $1.43 |
| Avg Volume | 811K |
| Beta | 1.3 |
|
52-Week Range
$1.09
| |
About PLIANT THERAPEUTICS, INC. (PLRX)
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PLIANT THERAPEUTICS, INC. (PLRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PLIANT THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PLIANT THERAPEUTICS, INC.'s debt ratio?
PLIANT THERAPEUTICS, INC.'s debt ratio is 73.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.2%.
What are PLIANT THERAPEUTICS, INC.'s key financial metrics?
PLIANT THERAPEUTICS, INC. has a market capitalization of $72M. Return on equity stands at -61.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.